• Home
  • 512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies.

512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies.

Author List
R. Aggarwal, S. Umetsu, M. Dhawan, J. Grabowsky, J. Carnevale, M. Howell, L. Wilch, J. Chapman, E. Alvarez, S. Calabrese, S. Smith, N. Shah, E. Dean, P. Munster, E. Collisson
Publication
Annals of Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/231933198
Publication Year
2021
Publication Title
R. Aggarwal, S. Umetsu, M. Dhawan, J. Grabowsky, J. Carnevale, M. Howell, L. Wilch, J. Chapman, E. Alvarez, S. Calabrese, S. Smith, N. Shah, E. Dean, P. Munster, E. Collisson. 512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies. Annals of Oncology. 2021 Sep 1; 32:s583.